March 12, 2018 / 12:20 PM / 9 months ago

BRIEF-Immune Design Reports Data Update For Lead Immunotherapy Programs

March 12 (Reuters) - Immune Design Corp:

* IMMUNE DESIGN REPORTS DATA UPDATE FOR LEAD IMMUNOTHERAPY PROGRAMS: IMPROVEMENT IN SURVIVAL FOR CMB305 MONOTHERAPY IN SARCOMA AND INCREASED OBJECTIVE RESPONSES FOR G100/PEMBROLIZUMAB COMBINATION IN FOLLICULAR LYMPHOMA

* IMMUNE DESIGN CORP - ‍CMB305 CONTINUES TO BE WELL TOLERATED, WITH ONLY ONE GRADE 3 ADVERSE EVENT​

* IMMUNE DESIGN CORP - ‍MEDIAN OVERALL SURVIVAL ACROSS ALL STS PATIENTS HAS BEEN REACHED AT 23.7 MONTHS FROM CMB305 MONOTHERAPY TRIAL​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below